New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 8, 2012
07:27 EDTCBLICleveland BioLabs reports Q3 EPS (30c) vs (8c) in Q3 of 2011
Reports Q3 R&D expenses down to about $4.8M. Revenues for Q3 decreased to approximately $0.2M from approximately $3.8M in Q3 of 2011, primarily due to decreases in research sponsored by the DoD, BARDA and a NY State/RPCI Sponsored Research Agreement.
News For CBLI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2015
09:23 EDTCBLICleveland BioLabs announces entolimod Phase 1 data to be presented at ASCO
Subscribe for More Information
April 14, 2015
09:13 EDTCBLIOn The Fly: Pre-market Movers.
UP AFTER EARNINGS: JPMorgan Chase (JPM), up 1%... Johnson & Johnson (JNJ), up marginally... Triangle Petroleum (TPLM), up 4.2%... Fastenal (FAST), up 5%. ALSO HIGHER: Brainstorm Cell Therapeutics (BCLI), up 13.5% after announcing that it will present NurOwn Phase 2a clinical data at the Academy of Neurology annual meeting... Builders FirstSource (BLDR), up 7.2% after being upgraded to Buy from Hold at Stifel... Solazyme (SZYM), up 7.5% after announcing a strategic agreement with Flotek (FTK)... Cleveland BioLabs (CBLI), up 6.8% after receiving funding recommendation from the Department of Defense... Nordic American Tanker (NAT), up 3.2% after raising quarterly dividend to 38c from 22c... Ocwen (OCN), up 3.8% after reporting preliminary fiscal 2014 results. DOWN AFTER EARNINGS: Wells Fargo (WFC), down just under 1%. ALSO LOWER: Norfolk Southern (NSC), down 5.8% after being downgraded to Hold from Buy at TD Securities... RXi Pharmaceuticals (RXII), down 14.3% after filing to sell $20M of common stock and warrants... Arrowhead Research (ARWR), down 4.5% after being downgraded to Hold from Buy at Jefferies.
07:45 EDTCBLICleveland BioLabs receives funding recommendation from DoD
Cleveland BioLabs announced that the company received notice that a second proposal application to support further development of entolimod as a medical radiation countermeasure has been recommended for funding, subject to negotiations, by the Department of Defense, or DoD, office of Congressionally Directed Medical Research Programs, or CDMRP. This award is subject to successful negotiations and availability of funds. This proposal application aims to conduct an additional clinical study to support submission of a Biological Licensure Application, or BLA, to the FDA. Entolimod is a novel investigational drug that addresses the Department of Defense concern against radiological threats.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use